{"id":15166,"date":"2019-01-23T13:35:42","date_gmt":"2019-01-23T12:35:42","guid":{"rendered":"https:\/\/news.embl.de\/?p=15166"},"modified":"2024-03-22T11:13:32","modified_gmt":"2024-03-22T10:13:32","slug":"new-open-targets-director-appointed","status":"publish","type":"post","link":"https:\/\/www.embl.org\/news\/lab-matters\/new-open-targets-director-appointed\/","title":{"rendered":"New Open Targets Director appointed"},"content":{"rendered":"\n<p><a href=\"https:\/\/opentargets.org\" target=\"_blank\" rel=\"noopener noreferrer\">Open Targets<\/a> has appointed Ian Dunham as its new Director. Dunham will focus on delivering the Open Targets\u2019 research programme to exploit advances in genetics for drug target identification. He also aims to increase the use of new approaches to the programme, including single-cell sequencing, <a href=\"https:\/\/news.embl.de\/science\/nothing-blue-skies\/\">CRISPR<\/a> and artificial intelligence.<\/p>\n\n\n\n<p>Open Targets, launched in 2014, is the public-private partnership between <a href=\"http:\/\/www.ebi.ac.uk\" target=\"_blank\" rel=\"noopener noreferrer\">EMBL\u2019s European Bioinformatics Institute (EMBL-EBI)<\/a>, the Wellcome Sanger Institute, GSK, Biogen, Takeda, Celgene and Sanofi. The initiative aims to transform drug discovery through the systematic identification and prioritisation of targets.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Ideally placed for innovation<\/h2>\n\n\n\n<p>\u201cOpen Targets is ideally placed for innovation,\u201d says Dunham. \u201cWe have built strong partnerships and established powerful research programmes that exploit advances in genetics and genomics to improve drug target identification. We\u2019re now tapping into the expertise of the Wellcome Genome Campus and our partners to bring other new technologies to our research. Some of the more promising directions include single-cell sequencing, gene editing and artificial intelligence.\u201d<\/p>\n\n\n\n<p>Dunham has been the Scientific Director of Open Targets since 2014. He played a pivotal role in establishing the initial research programme and oversaw new projects initiated by Open Targets. These include experimental projects in oncology, neurodegeneration, immunity and inflammation.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">A growing collaboration<\/h2>\n\n\n\n<p>Before joining Open Targets, Dunham held several roles at EMBL-EBI. His research areas included genome-wide mapping of regulatory elements and chromatin state in the human genome. He was also an integral part of the <a href=\"https:\/\/www.genome.gov\/10005107\/the-encode-project-encyclopedia-of-dna-elements\/\" target=\"_blank\" rel=\"noopener noreferrer\">NHGRI ENCODE project<\/a>, which focused on identifying all functional regions of the human genome, regardless of whether they formed genes or not. Dunham\u2019s interest in mapping the human genome has been a recurring theme throughout his career.<\/p>\n\n\n\n<p>\u201cOpen Targets is an excellent example of how computational and experimental researchers from different backgrounds and sectors can collaborate to improve drug discovery,\u201d concludes Rolf Apweiler, Interim Head of Open Targets and Joint Director of EMBL-EBI. \u201cI am delighted to see Ian stepping up to lead the collaboration. His expertise in genetics, genomics and his involvement with the project from its inception will be invaluable in developing the collaboration even further.\u201d<\/p>\n\n\n\n<p>This post was originally published on <a href=\"https:\/\/www.ebi.ac.uk\/about\/news\/press-releases\/ian-dunham-open-targets-director\" target=\"_blank\" rel=\"canonical nofollow noopener noreferrer\" data-href=\"https:\/\/www.ebi.ac.uk\/about\/news\/press-releases\/ian-dunham-open-targets-director\">EMBL-EBI News.<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>New director drives drug discovery partnership forward<\/p>\n","protected":false},"author":47,"featured_media":15172,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[3,17593],"tags":[474,981,312,763],"embl_taxonomy":[],"class_list":["post-15166","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-lab-matters","category-people-perspectives","tag-collaboration","tag-drug","tag-drug-discovery","tag-open-targets"],"acf":{"article_intro":"<p>Ian Dunham set to lead drug target identification initiative Open Targets<\/p>\n","related_links":[{"link_description":"Open Targets ","link_url":"https:\/\/www.opentargets.org\/"},{"link_description":"Open Targets Platform","link_url":"https:\/\/www.targetvalidation.org\/"},{"link_description":"Open Targets Genetics","link_url":"https:\/\/genetics.opentargets.org\/"}],"article_sources":false,"vf_locked":false,"featured":false,"color":"#007B53"},"embl_taxonomy_terms":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.2 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>New Open Targets Director appointed | EMBL<\/title>\n<meta name=\"description\" content=\"Open Targets, the private-public partnership for drug discovery, has appointed Ian Dunham as its new Director.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.embl.org\/news\/lab-matters\/new-open-targets-director-appointed\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"New Open Targets Director appointed | EMBL\" \/>\n<meta property=\"og:description\" content=\"Open Targets, the private-public partnership for drug discovery, has appointed Ian Dunham as its new Director.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.embl.org\/news\/lab-matters\/new-open-targets-director-appointed\/\" \/>\n<meta property=\"og:site_name\" content=\"EMBL\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/embl.org\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-01-23T12:35:42+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-03-22T10:13:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2019\/01\/DUNHAM_Ian_OT_Director_appointment_EMBL_620x425_2-e1548244792767.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"620\" \/>\n\t<meta property=\"og:image:height\" content=\"425\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Oana Stroe\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@embl\" \/>\n<meta name=\"twitter:site\" content=\"@embl\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Oana Stroe\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/www.embl.org\/news\/lab-matters\/new-open-targets-director-appointed\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.embl.org\/news\/lab-matters\/new-open-targets-director-appointed\/\"},\"author\":{\"name\":\"Oana Stroe\",\"@id\":\"https:\/\/www.embl.org\/news\/#\/schema\/person\/95d28f359cc138357c5dcf79319ef414\"},\"headline\":\"New Open Targets Director appointed\",\"datePublished\":\"2019-01-23T12:35:42+00:00\",\"dateModified\":\"2024-03-22T10:13:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.embl.org\/news\/lab-matters\/new-open-targets-director-appointed\/\"},\"wordCount\":359,\"publisher\":{\"@id\":\"https:\/\/www.embl.org\/news\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.embl.org\/news\/lab-matters\/new-open-targets-director-appointed\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2019\/01\/DUNHAM_Ian_OT_Director_appointment_EMBL_620x425_2-e1548244792767.jpg\",\"keywords\":[\"collaboration\",\"drug\",\"drug discovery\",\"open targets\"],\"articleSection\":[\"Lab Matters\",\"People &amp; Perspectives\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.embl.org\/news\/lab-matters\/new-open-targets-director-appointed\/\",\"url\":\"https:\/\/www.embl.org\/news\/lab-matters\/new-open-targets-director-appointed\/\",\"name\":\"New Open Targets Director appointed | EMBL\",\"isPartOf\":{\"@id\":\"https:\/\/www.embl.org\/news\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.embl.org\/news\/lab-matters\/new-open-targets-director-appointed\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.embl.org\/news\/lab-matters\/new-open-targets-director-appointed\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2019\/01\/DUNHAM_Ian_OT_Director_appointment_EMBL_620x425_2-e1548244792767.jpg\",\"datePublished\":\"2019-01-23T12:35:42+00:00\",\"dateModified\":\"2024-03-22T10:13:32+00:00\",\"description\":\"Open Targets, the private-public partnership for drug discovery, has appointed Ian Dunham as its new Director.\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.embl.org\/news\/lab-matters\/new-open-targets-director-appointed\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.embl.org\/news\/lab-matters\/new-open-targets-director-appointed\/#primaryimage\",\"url\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2019\/01\/DUNHAM_Ian_OT_Director_appointment_EMBL_620x425_2-e1548244792767.jpg\",\"contentUrl\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2019\/01\/DUNHAM_Ian_OT_Director_appointment_EMBL_620x425_2-e1548244792767.jpg\",\"width\":620,\"height\":425,\"caption\":\"Ian Dunham will focus on the delivery of Open Targets\u2019 established research programme to exploit advances in genetics for drug target identification and prioritisation. PHOTO: Oana Stroe\/EMBL-EBI\"},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.embl.org\/news\/#website\",\"url\":\"https:\/\/www.embl.org\/news\/\",\"name\":\"European Molecular Biology Laboratory News\",\"description\":\"News from the European Molecular Biology Laboratory\",\"publisher\":{\"@id\":\"https:\/\/www.embl.org\/news\/#organization\"},\"alternateName\":\"EMBL News\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.embl.org\/news\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.embl.org\/news\/#organization\",\"name\":\"European Molecular Biology Laboratory\",\"alternateName\":\"EMBL\",\"url\":\"https:\/\/www.embl.org\/news\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.embl.org\/news\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/09\/EMBL_logo_colour-1-300x144-1.png\",\"contentUrl\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/09\/EMBL_logo_colour-1-300x144-1.png\",\"width\":300,\"height\":144,\"caption\":\"European Molecular Biology Laboratory\"},\"image\":{\"@id\":\"https:\/\/www.embl.org\/news\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/embl.org\/\",\"https:\/\/x.com\/embl\",\"https:\/\/www.instagram.com\/embl_org\/\",\"https:\/\/www.linkedin.com\/company\/15813\/\",\"https:\/\/www.youtube.com\/user\/emblmedia\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.embl.org\/news\/#\/schema\/person\/95d28f359cc138357c5dcf79319ef414\",\"name\":\"Oana Stroe\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.embl.org\/news\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/105fb83bbeaf64062ef1f4608964e5163ac52f590628df2ffde6de9a0d85af80?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/105fb83bbeaf64062ef1f4608964e5163ac52f590628df2ffde6de9a0d85af80?s=96&d=mm&r=g\",\"caption\":\"Oana Stroe\"},\"description\":\"Oana Stroe is a PR specialist and copywriter with experience in engineering, IT and life sciences. She now collects and shares remarkable science stories.\",\"url\":\"https:\/\/www.embl.org\/news\/author\/oana-stroe-2-2-2-2-2-2-2-2-2-2-2-2-2-2-2-2-2-2-2-3\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"New Open Targets Director appointed | EMBL","description":"Open Targets, the private-public partnership for drug discovery, has appointed Ian Dunham as its new Director.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.embl.org\/news\/lab-matters\/new-open-targets-director-appointed\/","og_locale":"en_US","og_type":"article","og_title":"New Open Targets Director appointed | EMBL","og_description":"Open Targets, the private-public partnership for drug discovery, has appointed Ian Dunham as its new Director.","og_url":"https:\/\/www.embl.org\/news\/lab-matters\/new-open-targets-director-appointed\/","og_site_name":"EMBL","article_publisher":"https:\/\/www.facebook.com\/embl.org\/","article_published_time":"2019-01-23T12:35:42+00:00","article_modified_time":"2024-03-22T10:13:32+00:00","og_image":[{"width":620,"height":425,"url":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2019\/01\/DUNHAM_Ian_OT_Director_appointment_EMBL_620x425_2-e1548244792767.jpg","type":"image\/jpeg"}],"author":"Oana Stroe","twitter_card":"summary_large_image","twitter_creator":"@embl","twitter_site":"@embl","twitter_misc":{"Written by":"Oana Stroe","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/www.embl.org\/news\/lab-matters\/new-open-targets-director-appointed\/#article","isPartOf":{"@id":"https:\/\/www.embl.org\/news\/lab-matters\/new-open-targets-director-appointed\/"},"author":{"name":"Oana Stroe","@id":"https:\/\/www.embl.org\/news\/#\/schema\/person\/95d28f359cc138357c5dcf79319ef414"},"headline":"New Open Targets Director appointed","datePublished":"2019-01-23T12:35:42+00:00","dateModified":"2024-03-22T10:13:32+00:00","mainEntityOfPage":{"@id":"https:\/\/www.embl.org\/news\/lab-matters\/new-open-targets-director-appointed\/"},"wordCount":359,"publisher":{"@id":"https:\/\/www.embl.org\/news\/#organization"},"image":{"@id":"https:\/\/www.embl.org\/news\/lab-matters\/new-open-targets-director-appointed\/#primaryimage"},"thumbnailUrl":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2019\/01\/DUNHAM_Ian_OT_Director_appointment_EMBL_620x425_2-e1548244792767.jpg","keywords":["collaboration","drug","drug discovery","open targets"],"articleSection":["Lab Matters","People &amp; Perspectives"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.embl.org\/news\/lab-matters\/new-open-targets-director-appointed\/","url":"https:\/\/www.embl.org\/news\/lab-matters\/new-open-targets-director-appointed\/","name":"New Open Targets Director appointed | EMBL","isPartOf":{"@id":"https:\/\/www.embl.org\/news\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.embl.org\/news\/lab-matters\/new-open-targets-director-appointed\/#primaryimage"},"image":{"@id":"https:\/\/www.embl.org\/news\/lab-matters\/new-open-targets-director-appointed\/#primaryimage"},"thumbnailUrl":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2019\/01\/DUNHAM_Ian_OT_Director_appointment_EMBL_620x425_2-e1548244792767.jpg","datePublished":"2019-01-23T12:35:42+00:00","dateModified":"2024-03-22T10:13:32+00:00","description":"Open Targets, the private-public partnership for drug discovery, has appointed Ian Dunham as its new Director.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.embl.org\/news\/lab-matters\/new-open-targets-director-appointed\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.embl.org\/news\/lab-matters\/new-open-targets-director-appointed\/#primaryimage","url":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2019\/01\/DUNHAM_Ian_OT_Director_appointment_EMBL_620x425_2-e1548244792767.jpg","contentUrl":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2019\/01\/DUNHAM_Ian_OT_Director_appointment_EMBL_620x425_2-e1548244792767.jpg","width":620,"height":425,"caption":"Ian Dunham will focus on the delivery of Open Targets\u2019 established research programme to exploit advances in genetics for drug target identification and prioritisation. PHOTO: Oana Stroe\/EMBL-EBI"},{"@type":"WebSite","@id":"https:\/\/www.embl.org\/news\/#website","url":"https:\/\/www.embl.org\/news\/","name":"European Molecular Biology Laboratory News","description":"News from the European Molecular Biology Laboratory","publisher":{"@id":"https:\/\/www.embl.org\/news\/#organization"},"alternateName":"EMBL News","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.embl.org\/news\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.embl.org\/news\/#organization","name":"European Molecular Biology Laboratory","alternateName":"EMBL","url":"https:\/\/www.embl.org\/news\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.embl.org\/news\/#\/schema\/logo\/image\/","url":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/09\/EMBL_logo_colour-1-300x144-1.png","contentUrl":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/09\/EMBL_logo_colour-1-300x144-1.png","width":300,"height":144,"caption":"European Molecular Biology Laboratory"},"image":{"@id":"https:\/\/www.embl.org\/news\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/embl.org\/","https:\/\/x.com\/embl","https:\/\/www.instagram.com\/embl_org\/","https:\/\/www.linkedin.com\/company\/15813\/","https:\/\/www.youtube.com\/user\/emblmedia\/"]},{"@type":"Person","@id":"https:\/\/www.embl.org\/news\/#\/schema\/person\/95d28f359cc138357c5dcf79319ef414","name":"Oana Stroe","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.embl.org\/news\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/105fb83bbeaf64062ef1f4608964e5163ac52f590628df2ffde6de9a0d85af80?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/105fb83bbeaf64062ef1f4608964e5163ac52f590628df2ffde6de9a0d85af80?s=96&d=mm&r=g","caption":"Oana Stroe"},"description":"Oana Stroe is a PR specialist and copywriter with experience in engineering, IT and life sciences. She now collects and shares remarkable science stories.","url":"https:\/\/www.embl.org\/news\/author\/oana-stroe-2-2-2-2-2-2-2-2-2-2-2-2-2-2-2-2-2-2-2-3\/"}]}},"field_target_display":"embl","field_article_language":{"value":"english","label":"English"},"fimg_url":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2019\/01\/DUNHAM_Ian_OT_Director_appointment_EMBL_620x425_2-e1548244792767.jpg","featured_image_src":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2019\/01\/DUNHAM_Ian_OT_Director_appointment_EMBL_620x425_2-e1548244792767.jpg","_links":{"self":[{"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/posts\/15166","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/users\/47"}],"replies":[{"embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/comments?post=15166"}],"version-history":[{"count":6,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/posts\/15166\/revisions"}],"predecessor-version":[{"id":19317,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/posts\/15166\/revisions\/19317"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/media\/15172"}],"wp:attachment":[{"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/media?parent=15166"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/categories?post=15166"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/tags?post=15166"},{"taxonomy":"embl_taxonomy","embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/embl_taxonomy?post=15166"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}